Rational design of a JAK1-selective siRNA inhibitor for the modulation of autoimmunity in the skin
© 2023. The Author(s)..
Inhibition of Janus kinase (JAK) family enzymes is a popular strategy for treating inflammatory and autoimmune skin diseases. In the clinic, small molecule JAK inhibitors show distinct efficacy and safety profiles, likely reflecting variable selectivity for JAK subtypes. Absolute JAK subtype selectivity has not yet been achieved. Here, we rationally design small interfering RNAs (siRNAs) that offer sequence-specific gene silencing of JAK1, narrowing the spectrum of action on JAK-dependent cytokine signaling to maintain efficacy and improve safety. Our fully chemically modified siRNA supports efficient silencing of JAK1 expression in human skin explant and modulation of JAK1-dependent inflammatory signaling. A single injection into mouse skin enables five weeks of duration of effect. In a mouse model of vitiligo, local administration of the JAK1 siRNA significantly reduces skin infiltration of autoreactive CD8+ T cells and prevents epidermal depigmentation. This work establishes a path toward siRNA treatments as a new class of therapeutic modality for inflammatory and autoimmune skin diseases.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Nature communications - 14(2023), 1 vom: 04. Nov., Seite 7099 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 06.11.2023 Date Revised 10.04.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41467-023-42714-4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36417370X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36417370X | ||
| 003 | DE-627 | ||
| 005 | 20240410232250.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41467-023-42714-4 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1371.xml |
| 035 | |a (DE-627)NLM36417370X | ||
| 035 | |a (NLM)37925520 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tang, Qi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Rational design of a JAK1-selective siRNA inhibitor for the modulation of autoimmunity in the skin |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.11.2023 | ||
| 500 | |a Date Revised 10.04.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a Inhibition of Janus kinase (JAK) family enzymes is a popular strategy for treating inflammatory and autoimmune skin diseases. In the clinic, small molecule JAK inhibitors show distinct efficacy and safety profiles, likely reflecting variable selectivity for JAK subtypes. Absolute JAK subtype selectivity has not yet been achieved. Here, we rationally design small interfering RNAs (siRNAs) that offer sequence-specific gene silencing of JAK1, narrowing the spectrum of action on JAK-dependent cytokine signaling to maintain efficacy and improve safety. Our fully chemically modified siRNA supports efficient silencing of JAK1 expression in human skin explant and modulation of JAK1-dependent inflammatory signaling. A single injection into mouse skin enables five weeks of duration of effect. In a mouse model of vitiligo, local administration of the JAK1 siRNA significantly reduces skin infiltration of autoreactive CD8+ T cells and prevents epidermal depigmentation. This work establishes a path toward siRNA treatments as a new class of therapeutic modality for inflammatory and autoimmune skin diseases | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a RNA, Small Interfering |2 NLM | |
| 650 | 7 | |a Janus Kinase Inhibitors |2 NLM | |
| 650 | 7 | |a Janus Kinase 1 |2 NLM | |
| 650 | 7 | |a EC 2.7.10.2 |2 NLM | |
| 650 | 7 | |a RNA, Double-Stranded |2 NLM | |
| 650 | 7 | |a JAK1 protein, human |2 NLM | |
| 650 | 7 | |a EC 2.7.10.2 |2 NLM | |
| 700 | 1 | |a Fakih, Hassan H |e verfasserin |4 aut | |
| 700 | 1 | |a Zain Ui Abideen, Mohammad |e verfasserin |4 aut | |
| 700 | 1 | |a Hildebrand, Samuel R |e verfasserin |4 aut | |
| 700 | 1 | |a Afshari, Khashayar |e verfasserin |4 aut | |
| 700 | 1 | |a Gross, Katherine Y |e verfasserin |4 aut | |
| 700 | 1 | |a Sousa, Jacquelyn |e verfasserin |4 aut | |
| 700 | 1 | |a Maebius, Allison S |e verfasserin |4 aut | |
| 700 | 1 | |a Bartholdy, Christina |e verfasserin |4 aut | |
| 700 | 1 | |a Søgaard, Pia Pernille |e verfasserin |4 aut | |
| 700 | 1 | |a Jackerott, Malene |e verfasserin |4 aut | |
| 700 | 1 | |a Hariharan, Vignesh |e verfasserin |4 aut | |
| 700 | 1 | |a Summers, Ashley |e verfasserin |4 aut | |
| 700 | 1 | |a Fan, Xueli |e verfasserin |4 aut | |
| 700 | 1 | |a Okamura, Ken |e verfasserin |4 aut | |
| 700 | 1 | |a Monopoli, Kathryn R |e verfasserin |4 aut | |
| 700 | 1 | |a Cooper, David A |e verfasserin |4 aut | |
| 700 | 1 | |a Echeverria, Dimas |e verfasserin |4 aut | |
| 700 | 1 | |a Bramato, Brianna |e verfasserin |4 aut | |
| 700 | 1 | |a McHugh, Nicholas |e verfasserin |4 aut | |
| 700 | 1 | |a Furgal, Raymond C |e verfasserin |4 aut | |
| 700 | 1 | |a Dresser, Karen |e verfasserin |4 aut | |
| 700 | 1 | |a Winter, Sarah J |e verfasserin |4 aut | |
| 700 | 1 | |a Biscans, Annabelle |e verfasserin |4 aut | |
| 700 | 1 | |a Chuprin, Jane |e verfasserin |4 aut | |
| 700 | 1 | |a Haddadi, Nazgol-Sadat |e verfasserin |4 aut | |
| 700 | 1 | |a Sherman, Shany |e verfasserin |4 aut | |
| 700 | 1 | |a Yıldız-Altay, Ümmügülsüm |e verfasserin |4 aut | |
| 700 | 1 | |a Rashighi, Mehdi |e verfasserin |4 aut | |
| 700 | 1 | |a Richmond, Jillian M |e verfasserin |4 aut | |
| 700 | 1 | |a Bouix-Peter, Claire |e verfasserin |4 aut | |
| 700 | 1 | |a Blanchard, Carine |e verfasserin |4 aut | |
| 700 | 1 | |a Clauss, Adam |e verfasserin |4 aut | |
| 700 | 1 | |a Alterman, Julia F |e verfasserin |4 aut | |
| 700 | 1 | |a Khvorova, Anastasia |e verfasserin |4 aut | |
| 700 | 1 | |a Harris, John E |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nature communications |d 2010 |g 14(2023), 1 vom: 04. Nov., Seite 7099 |w (DE-627)NLM199274525 |x 2041-1723 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2023 |g number:1 |g day:04 |g month:11 |g pages:7099 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41467-023-42714-4 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2023 |e 1 |b 04 |c 11 |h 7099 | ||